Scholarlink

<p>This study evaluates the efficacy and tolerability of low-dose oral cyclophosphamide, with or without bevacizumab, in treating recurrent ovarian and cervical cancer among patients heavily pretreated with platinum-based chemotherapy. It presents case reports of individuals who received low-dose cyclophosphamide (50&#xa0;mg/day) and bevacizumab (15&#xa0;mg/kg per cycle for three to four weeks) in a metronomic treatment approach. Focusing on three significant cases from a cohort of eleven treated with these regimens, the case report demonstrates partial responses, delayed disease progression, and minimal adverse effects. These findings highlight the regimen's potential to maintain quality of life and performance status. The study underscores the therapeutic benefits and mild toxicity profile of low-dose cyclophosphamide with or without bevacizumab, suggesting its potential as a viable treatment option for patients with extensive treatment history. This regimen is particularly promising in settings prioritizing quality of life.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Low-dose oral cyclophosphamide with or without bevacizumab treatment in patients with recurrent ovarian and cervical cancer before best supportive care

  • 期刊论文

  • 发表日期：

    2025年5月30日

查看全文
  • Yusuke Kawaguchi,
  • Ryusuke Murakami,
  • Akihiro Yanai,
  • Haruka Mieda,
  • Azusa Sakurai,
  • Saki Sawayama,
  • Mie Sakai,
  • Hirofumi Nonogaki,
  • Yumi Takao

摘要

This study evaluates the efficacy and tolerability of low-dose oral cyclophosphamide, with or without bevacizumab, in treating recurrent ovarian and cervical cancer among patients heavily pretreated with platinum-based chemotherapy. It presents case reports of individuals who received low-dose cyclophosphamide (50 mg/day) and bevacizumab (15 mg/kg per cycle for three to four weeks) in a metronomic treatment approach. Focusing on three significant cases from a cohort of eleven treated with these regimens, the case report demonstrates partial responses, delayed disease progression, and minimal adverse effects. These findings highlight the regimen's potential to maintain quality of life and performance status. The study underscores the therapeutic benefits and mild toxicity profile of low-dose cyclophosphamide with or without bevacizumab, suggesting its potential as a viable treatment option for patients with extensive treatment history. This regimen is particularly promising in settings prioritizing quality of life.